Coreo AG — Board/Management Information 2012

Mar 26, 2012

News Details

Corporate | 26 March 2012 12:20

Nanostart-holding MagForce AG announces company restructuring and revised corporate strategy for 2012

Nanostart AG / Key word(s): Miscellaneous

26.03.2012 / 12:20

---

– Greater emphasis on clinical development to provide key physicians with access to NanoTherm therapy – Start of post marketing glioblastoma study Q3 2012 to support expanded market acceptance with leading medical experts – Enhanced activities for international partnerships and initiation of discussions with FDA – Focus on development partnerships and strategic investors to expand patient access and further reduce development costs – Significant decrease in operating expenses expected in 2012 through headcount reduction
Frankfurt / Berlin – March 26, 2012 – Nanostart-holding MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company focusing on nanomedicine in oncology announced today the company's restructuring and revised corporate strategy for 2012. The company reduced its headcount from 52 employees (year-end 2011) to 30 (April 1, 2012) and expects a significant reduction in company expenses in 2012 as compared to 2011. The implemented cost reductions will enable the company to work more effectively and concentrate on clinical development activities to support the market introduction of NanoTherm(R) therapy. MagForce has revised its corporate strategy to put more emphasis on clinical development and its synergies with Marketing and Sales. The company has received EU approval for its technology, NanoTherm(R) therapy, for the treatment of brain tumors. Product revenues in 2011 were lower than expected due to the lack of involvement among leading medical experts in the development of the therapy. MagForce is now working closely with these key opinion leaders who have agreed to participate in a post-approval multi-center study to validate the novel technology in the medical community and gain first-hand experience. 'Our successful capital increase earlier this month along with reductions in expenditures will allow us to initiate both a glioblastoma post-market authorization study along with a study in prostate carcinoma this year. These upcoming trials, conducted in centers throughout Germany, will lay the foundation for wider acceptance of the therapy and expanded commercial use,' said Dr. Andreas Jordan, Management Board and founder of MagForce. 'In addition, we are in discussion with international companies and investors for strategic partnerships to share in the development costs and support international market approvals, including for the US market.' 'I am delighted to be working closely with leading European key opinion leaders who are pleased to support us in the further development of NanoTherm(R) therapy and participate in Magforce clinical studies,' said Prof. Dr. Hoda Tawfik, VP Clinical Development and Medical Affairs. 'Within the multi-center studies, we expect to place two to three new NanoActivator therapy systems in strategic centers before the end of this year.' In 2012, MagForce is pursuing international partnerships, specifically in the US, and plans to initiate discussions with the FDA. Furthermore, the company is in discussion with strategic investors who were not able to participate in recently announced fully-subscribed capital increase, but are interested in future investment opportunities with the company. About Nanostart: Nanostart AG headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. About MagForce: MagForce AG (XETRA: MF6) is a leading medical technology company focusing on nanomedicine in oncology. The company's proprietary procedure, NanoTherm(R) therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com . Disclaimer: This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the 'Entry Standard' segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan. Media contact: Nanostart AG Dr. Hans Joachim Duerr Head of Corporate Communications Goethestrasse 26-28 D-60313 Frankfurt, Germany phone: +49 (0)69-21 93 96 111 fax: +49 (0)69-21 93 96 150 e-mail: presse@nanostart.de

End of Corporate News

---

26.03.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.

The issuer is solely responsible for the content of this announcement.

DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de

---

162219  26.03.2012